# Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

> **NCT02049905** · PHASE3 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 433 (actual)

## Conditions studied

- Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

## Interventions

- **DRUG:** Aldoxorubicin
- **DRUG:** Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

## Key facts

- **NCT ID:** NCT02049905
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 433 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049905, "Phase 3 Study to Treat Patients With Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02049905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*